PLK1 Is a Potential Prognostic Factor Associated with the Tumor Microenvironment in Lung Adenocarcinoma
Lina Wang1, Man Gao2, Dongjie Sun1
1The Key Laboratory of Pathobiology, Ministry of Education, Department of Pathology, College of Basic Medical Sciences, Jilin University, Changchun, Jilin, China.
Biomed Research International
|August 9, 2022
Summary
This study identifies Polo-like kinase 1 (PLK1) as a promising prognostic biomarker and potential treatment target for lung adenocarcinoma (LUAD). PLK1 expression correlates with tumor-infiltrating immune cells and patient survival, suggesting its role in LUAD progression.
Area of Science:
- Oncology
- Molecular Biology
- Immunology
Background:
- Lung adenocarcinoma (LUAD) represents over 40% of global lung cancer cases.
- LUAD patients often have a poor prognosis due to limited effective treatments.
Purpose of the Study:
- To identify novel prognostic biomarkers and therapeutic targets for LUAD.
- To investigate the relationship between gene expression, tumor-infiltrating immune cells, and patient outcomes in LUAD.
Main Methods:
- Analysis of differentially expressed genes (DEGs) from the Cancer Genome Atlas (TCGA) database.
- Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment, Gene Set Variation Analysis (GSVA), CIBERSORT, and protein-protein interaction (PPI) network construction.
- Quantitative real-time PCR (qPCR) and immunoblotting for validation.
Main Results:
- Polo-like kinase 1 (PLK1) was identified as a significant prognostic factor for LUAD.
- PLK1 expression positively correlated with CD8+ and activated memory CD4+ T cells, and negatively with activated natural killer cells.
- PLK1 overexpression was linked to increased immune cytotoxicity and negatively correlated with overall survival.
Conclusions:
- PLK1 is a potential prognostic biomarker and therapeutic target for lung adenocarcinoma.
- PLK1 influences the tumor microenvironment and immune cell infiltration in LUAD.
- Targeting PLK1 may offer a novel therapeutic strategy for improving LUAD patient outcomes.
More Related Videos
13:18Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma
Published on: March 3, 2023
1.3K
06:03Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression
Published on: January 19, 2019
17.3K
Related Concept Videos
01:22PI3K/mTOR/AKT Signaling Pathway
3.9K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.9K
02:17The Tumor Microenvironment
6.8K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.8K
02:39lncRNA - Long Non-coding RNAs
8.8K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.8K
01:19Interactions Between Signaling Pathways
6.4K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.4K
03:03mTOR Signaling and Cancer Progression
3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.9K
02:23Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K